JMP Securities analyst Jason Butler reiterated a Buy rating on Halozyme (NASDAQ:HALO) Therapeutics on Wednesday, setting a price target of $55, which is approximately 40.92% above the present share price of $39.03.
Butler expects Halozyme Therapeutics to post earnings per share (EPS) of $0.64 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Halozyme, with an average price target of $57.
The analysts price targets range from a high of $66 to a low of $50.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $136.46 million and a net profit of $93.05 million. The company's market cap is $5.56 billion.
According to TipRanks.com, JMP Securities analyst Jason Butler is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 5.6% and a 46.13% success rate.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.